News from leap therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 13, 2022, 07:00 ET Leap Therapeutics Reports First Quarter 2022 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Mar 11, 2022, 07:00 ET Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Mar 02, 2022, 07:00 ET Leap Therapeutics to Present at Raymond James 43rd Annual Institutional Investors Conference

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Jan 31, 2022, 07:00 ET Leica Biosystems and Leap Therapeutics Partner on Companion Diagnostic to Advance Care for Cancer Patients

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (NASDAQ: LPTX), a biotechnology company, to...

Jan 24, 2022, 07:00 ET Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Jan 18, 2022, 17:00 ET Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Jan 05, 2022, 07:00 ET Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Jan 03, 2022, 07:00 ET Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that ...

Nov 15, 2021, 07:00 ET Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Nov 12, 2021, 07:00 ET Leap Therapeutics Reports Third Quarter 2021 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Sep 24, 2021, 12:00 ET Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Sep 22, 2021, 08:30 ET Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Sep 21, 2021, 16:01 ET Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Sep 16, 2021, 02:31 ET Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Sep 13, 2021, 06:00 ET Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Sep 07, 2021, 07:00 ET Leap Therapeutics to Participate at Two Upcoming Virtual Investor Conferences

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Aug 13, 2021, 07:00 ET Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

Jul 26, 2021, 07:00 ET Leap Therapeutics to Present at the ESMO 2021 Virtual Congress

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Jul 07, 2021, 07:00 ET Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

Jun 14, 2021, 07:00 ET Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that...

May 14, 2021, 08:00 ET Leap Therapeutics Reports First Quarter 2021 Financial Results

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

May 12, 2021, 08:00 ET Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment

Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences,...

Apr 12, 2021, 08:00 ET Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment

Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused ...

Apr 01, 2021, 07:00 ET Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...

Mar 22, 2021, 06:00 ET Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the...